May 31, 2012Open Access

Drotrecogin Alfa (Activated) in Adults with Septic Shock

Key Points

Key points are not available for this paper at this time.

Abstract

DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Ranieri et al. (Thu,) studied this question.

synapsesocial.com/papers/69da10cd2a25b240b7a3e225 — DOI: https://doi.org/10.1056/nejmoa1202290

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Survival Methods· 2007 · 51 citations
The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)· 2001 · 213 citations
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial· 2007 · 501 citations
Human recombinant activated protein C for severe sepsis· 2012 · 216 citations
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *· 2004 · 154 citations

Authors

V. Marco Ranieri

University of Bari Aldo Moro

Bruce Thompson

The University of Melbourne

Philip S. Barie

University of New Brunswick

Journals

New England Journal of Medicine

Actions

Institutions

Cornell University

Massachusetts General Hospital

New York University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Drotrecogin Alfa (Activated) in Adults with Septic Shock

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider